Rabbit Polyclonal ANGPT2 Antibody

+ +

•  

   
     All lanes : Anti-ANGPT2 Antibody (C-term) at 1:500 dilution Lane 1: mouse ovary tissue lysate Lane 2: rat kidney tissue lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated (ASP1615)  at 1/15000 dilution. Observed band size : 61kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     All lanes : Anti-ANGPT2 Antibody (C-term) at 1:500 dilution Lane 1: mouse ovary tissue lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated (ASP1615)  at 1/15000 dilution. Observed band size : 61kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     ANGPT2 Antibody (C-term) (Cat. #P34915) western blot analysis in mouse kidney tissue lysates (35ug/lane).This demonstrates the ANGPT2 antibody detected the ANGPT2 protein (arrow).    

•  

   
     Overlay histogram showing A549 cells stained with P34915 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34915,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     ANGPT2 antibody (C-term) (Cat. #P34915) immunohistochemistry analysis in formalin fixed and paraffin embedded human uterus tissue followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of the ANGPT2 antibody (C-term) for immunohistochemistry.  Clinical relevance has not been evaluated.    

ANGPT2 (Angiopoietin-2) is a glycoprotein belonging to the angiopoietin family, primarily known for its role in regulating vascular and lymphatic angiogenesis. It functions as a context-dependent agonist/antagonist of the Tie2 receptor, modulating endothelial cell signaling. Under physiological conditions, ANGPT2 is involved in vascular remodeling, inflammation, and permeability. However, dysregulation of ANGPT2 expression is implicated in pathological states such as tumor angiogenesis, chronic inflammation, and vascular-related disorders like diabetic retinopathy and sepsis.

ANGPT2 antibodies are therapeutic or research tools designed to target and neutralize ANGPT2 activity. These antibodies block ANGPT2-Tie2 interactions, thereby inhibiting pro-angiogenic and pro-inflammatory pathways. In cancer, ANGPT2 overexpression correlates with tumor progression and metastasis; anti-ANGPT2 antibodies may suppress tumor vasculature and enhance chemotherapy efficacy. In ocular diseases, such as age-related macular degeneration (AMD), ANGPT2 inhibition is explored alongside VEGF-targeting therapies to address vascular leakage.

Notable ANGPT2-targeting agents include bispecific antibodies (e.g., faricimab, which targets both ANGPT2 and VEGF-A) currently in clinical trials. Research also highlights ANGPT2's role in modulating immune cell recruitment, suggesting broader applications in inflammatory and autoimmune diseases. However, challenges remain in understanding tissue-specific effects and optimizing therapeutic windows. Overall, ANGPT2 antibodies represent a promising, multifaceted approach to treating angiogenesis- and inflammation-driven pathologies.